Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Shaji Kumar(Mayo Clinic), Pieter Sonneveld(Erasmus MC Cancer Institute), Jenny Bird, Bill Bensinger, Asher Chanan‐Khan(WinnMed), Andrew Belch, Mario Boccadoro(University of Turin), Juan José Lahuerta(Research Institute Hospital 12 de Octubre), Jesús F. San Miguel(Clinica Universidad de Navarra), David S. Siegel(Hackensack Meridian Health), J H Lee(Deleted Institution), Brian G.M. Durie(Cedars-Sinai Medical Center), Sundar Jagannath(Mount Sinai Hospital), Joan Bladé(Hospital Clínic de Barcelona), Meral Beksaç(Ankara University), Robert Z. Orlowski(University of North Carolina at Chapel Hill), Antje Hoering(Cancer Research And Biostatistics), Paul G. Richardson(Harvard University), Orhan Sezer(Charité - Universitätsmedizin Berlin), Saskia K. Klein(Erasmus MC), Rafat Abonour(Sylvester Comprehensive Cancer Center), Xavier Leleu(Inserm), Hartmut Goldschmidt(Heidelberg University), Antonio Palumbo(University Hospital Brno), Niels Abildgaard(University of Southern Denmark), Hervé Avet‐Loiseau(Institut universitaire du cancer de Toulouse Oncopole), Ashraf Badros(University of Maryland, Baltimore), S. Vincent Rajkumar(WinnMed), Michèle Cavo(Unknown), Dalsu Baris, Tony Child, Melissa Alsina(Moffitt Cancer Center), Gareth J. Morgan(Hywel Dda University Health Board), Philippe Moreau(Centre National de la Recherche Scientifique), Michael Attal, Régis Bataille(Inserm), C Anderson Kenneth, J Feather(Boston University), Cyrille Hulin(Centre Hospitalier Régional et Universitaire de Nancy), Dina Ben‐Yehuda(Hebrew University of Jerusalem), John Crowley(AbbVie (United States)), J. Haessler(Cancer Research And Biostatistics), R. Alexanian, P. Leif Bergsagel(Mayo Clinic in Arizona), Bart Barlogie(University of Arkansas for Medical Sciences), Wen Ming Chen
Cited by 721
Related Papers
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k